14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
As of Sep 17, 2026, Mind Medicine (MindMed) Inc. Common Shares (MNMD) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SNYR carries a Unified Composite Score of 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin), whereas MNMD carries 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SNYR vs MNMD. Trailing 12-month operating profitability (SNYR -10.3% vs MNMD 0.0%) and valuation multiples (SNYR 0.6x vs MNMD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SNYR vs MNMD Key Questions & Quantitative Answers
As of Sep 17, 2026, Mind Medicine (MindMed) Inc. Common Shares (MNMD) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SNYR carries a Unified Composite Score of 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin), whereas MNMD carries 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin). Technically, SNYR sits in a Neutral phase (RSI 46.3, UNCLASSIFIED options structure) and MNMD sits in a Markup phase (RSI 65.3, UNCLASSIFIED options structure).
MNMD leads the Growth & Scale pillar: SNYR posts -32.8% YoY revenue growth and -90.6% YoY earnings growth on $28M TTM revenue (65.4% gross margin, -10.3% operating margin), compared with MNMD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SNYR generates $28M in USD-normalized revenue versus N/A for MNMD. In operating R&D and SG&A reinvestment, SNYR deploys 75.7% of Rev ($21M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MNMD.
SNYR screens cheaper on headline valuation multiples. SNYR trades at 0.6x Forward P/E, 0.6x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-13.7% FCF margin), whereas MNMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SNYR (-361.1% ROE) versus MNMD (-85.6% ROE) capital efficiency.
In options market volatility and institutional positioning, SNYR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.86β · 868% Vol realized risk). By comparison, MNMD carries 70.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.79β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Sep 17, 2026. For educational research only; not investment advice.